4-(溴甲基)-2-苯基-2H-1,2,3-噻唑 | 41425-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(溴甲基)-2-苯基-2H-1,2,3-噻唑
• 英文名称: 4-bromomethyl-2-phenyl-2H-1,2,3-triazole
• 英文别名: 4-bromomethyl-2-phenyl-2H-[1,2,3]triazole；4-Brommethyl-2-phenyl-2H-[1,2,3]triazol；2-Phenyl-4-brommethyl-2H-1,2,3-triazol；4-Brommethyl-2-phenyl-2H-1,2,3-triazol；4-(bromomethyl)-2-phenyl-2H-1,2,3-triazole；4-(bromomethyl)-2-phenyltriazole
• CAS: 41425-60-9
• 化学式: C₉H₈BrN₃
• mdl: MFCD02253419
• 分子量: 238.087
• InChiKey: UTQJRGAXADNRCO-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38 °C
• 沸点：
  363.5±34.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(溴甲基)-2-苯基-2H-1,2,3-噻唑 在 吡啶 、 氯磺酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Human β3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides

  摘要：

  Compounds containing a 1,2,3-triazole-substituted benzenesulfonamide were prepared and found to be potent and selective human beta(3)-adrenergic receptor agonists. The most interesting compound, trifluoromethylbenzyl analogue 12e (beta(3) EC50 = 3.1 nM with >1500-fold selectivity over binding to both beta(1)- and beta(2) receptors), stimulates lipolysis in the rhesus monkey (ED50 = 0.36 mg/kg) and is 25% orally bioavailable in the dog. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00422-4
• 作为产物：
  描述：

  2-苯基-1,2,3-三唑-4-甲醛 在 甲醇 、 sodium tetrahydroborate 、 四溴化碳 、 三苯基膦 作用下， 以 乙醚 为溶剂， 生成 4-(溴甲基)-2-苯基-2H-1,2,3-噻唑
  参考文献：
  名称：

  Human β3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides

  摘要：

  Compounds containing a 1,2,3-triazole-substituted benzenesulfonamide were prepared and found to be potent and selective human beta(3)-adrenergic receptor agonists. The most interesting compound, trifluoromethylbenzyl analogue 12e (beta(3) EC50 = 3.1 nM with >1500-fold selectivity over binding to both beta(1)- and beta(2) receptors), stimulates lipolysis in the rhesus monkey (ED50 = 0.36 mg/kg) and is 25% orally bioavailable in the dog. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00422-4

文献信息

• [EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE RÉCEPTEURS ADRÉNERGIQUES BÊTA 3 DÉRIVÉS DE PYRROLIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011025690A1

  公开（公告）日：2011-03-03

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了化合物的公式（I），其药物组成部分以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病中的方法。
• NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Edmondson Scott D.

  公开号：US20120157432A1

  公开（公告）日：2012-06-21

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供公式（I）的化合物、其制药组合物以及使用该化合物治疗或预防通过激活β3-肾上腺素受体介导的疾病的方法。
• Pyrrolidine derived beta 3 adrenergic receptor agonists
  申请人：Edmondson Scott D.

  公开号：US08354403B2

  公开（公告）日：2013-01-15

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式(I)的化合物，其制药组合物以及使用方法，用于治疗或预防通过激活β3肾上腺素能受体介导的疾病。
• Some Further Studies of 2-Phenyl-1,2,3,2H-Triazole Derivatives
  作者：J. L. Riebsomer、D. A. Stauffer

  DOI：10.1021/jo50004a023

  日期：1951.10
• Synthesis and Structure−activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains
  作者：Hamish S. Sutherland、Adrian Blaser、Iveta Kmentova、Scott G. Franzblau、Baojie Wan、Yuehong Wang、Zhenkun Ma、Brian D. Palmer、William A. Denny、Andrew M. Thompson

  DOI：10.1021/jm901378u

  日期：2010.1.28

  Recently described biphenyl analogues Of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.